The SOX9 Knockout Huh-7 Cell Line is a CRISPR/Cas9-edited human hepatocellular carcinoma knockout cell line in which the gene encoding the SOX9 transcription factor has been disrupted, generating a stable loss-of-function model for functional studies. This product provides a genetically defined system to interrogate SOX9-dependent mechanisms without the background expression of the intact allele, enabling dissection of its roles in stemness, differentiation, and oncogenic signaling.
The parental Huh-7 cell line is derived from a well-differentiated hepatocellular carcinoma arising in a 57-year-old Japanese male. These epithelial cells harbor wild-type p53 and are naturally permissive to hepatitis C virus replication, making them a widely used system for hepatic tumor biology. Huh-7 cells maintain key hepatocyte features, express liver-specific markers, and recapitulate clinically relevant signaling dependencies frequently activated in liver cancer, providing a physiologically appropriate host for interrogating SOX9 function.
SOX9 is a master transcription factor essential for chondrocyte differentiation, testis formation, and stem cell maintenance. It directly regulates genes controlling extracellular matrix remodeling and epithelial-mesenchymal transition (EMT), including COL2A1, ACAN, CD44, MMP2, and VIM. SOX9 activity is controlled by multiple upstream cascades: it is transcriptionally activated by Wnt/??-catenin through TCF/LEF complexes, by TGF?? via SMAD2/3, by Notch signaling through RBPJ, and by Hedgehog through GLI1. Additionally, it physically interacts with co-factors such as SOX5, SOX6, p300/CBP, ??-catenin, and SMAD3, integrating signals from Wnt, TGF??, Notch, Hedgehog, Hippo (YAP/TAZ), and PI3K/AKT (AKT1, mTOR) pathways.
In the Huh-7 hepatocellular carcinoma context, SOX9 drives a gene expression program that promotes cancer stem cell properties and EMT, both of which are linked to tumor initiation, metastasis, and therapy resistance. Disruption of SOX9 in this cell line abrogates Wnt/??-catenin and TGF?? signaling outputs, leading to decreased expression of stem cell markers (EPCAM, CD44), reduced mesenchymal markers (VIM, CDH2), and impaired matrix metalloproteinase production (MMP2, MMP9). Consequently, SOX9-null Huh-7 cells exhibit diminished proliferation, migration, and chemoresistance to agents such as sorafenib and cisplatin, mirroring the clinical challenges in hepatocellular carcinoma treatment.
This knockout cell line is ideally suited for hepatocellular carcinoma stem cell research, epithelial-mesenchymal transition studies, drug resistance investigations, and tumor microenvironment analyses. Typical assays include Western blotting and RT-qPCR for target gene validation, RNA-seq for transcriptome profiling, and flow cytometry for stem cell markers CD44 and EPCAM. Functional assays such as Transwell migration, colony formation, and tumorsphere assays can be applied to quantify metastatic potential and self-renewal. For further information regarding validation and product availability, please contact Ascent Research.
